Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMvigor211: Atezolizumab vs chemotherapy in advanced urothelial carcinoma after platinum failure
jRCT2080222688Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Dec 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of atezolizumab in transitional cell carcinoma (TCC) and bladder cancer (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Started Dec 2014; status: completed.
02
Drugs
atezolizumab
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on jRCT2080222688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222688.